Endologix Appoints Vice President of Global Marketing

Endologix, Inc. (Nasdaq:ELGX), developer of minimally invasive treatments for aortic disorders, announces the appointment of Daniel Hawkins (42) to the newly created position of Vice President of Global Marketing, effective immediately. Mr. Hawkins brings more than 15 years of marketing management and business development experience in the medical device and biotechnology industries.

�Daniel brings a successful track record of developing and launching new medical technologies,� said John McDermott, Endologix President and Chief Executive Officer. �He is a results-oriented leader with wide-breadth experience who will strengthen our senior management team and drive our new product development portfolio and business development activities. Daniel also has a strong commercial background that will be instrumental in achieving continued market share gains and support the successful commercialization of our Powerlink XL�, our suprarenal proximal extensions and the recently introduced IntuiTrak� Delivery System.�

Mr. Hawkins said, �Innovative products such as the IntuiTrak are a testament to the strength of Endologix�s product development team and are the foundation for profitable growth. I�m excited about joining the senior management team at Endologix to lead the commercialization of existing products as well as pursuing product development opportunities.�

Mr. Hawkins spent the past seven years in founder and leadership roles developing and commercializing medical devices for incubators funded by Three Arch Partners, Frazier Healthcare, Prospect Ventures, MPM Capital and Charter Ventures. He is a founder of Calibra Medical Inc., where he co-invented the core technology and was instrumental in creating a new medical device category with a market opportunity in excess of several billion dollars annually. He also played critical roles in developing product and marketing strategies for Restore Medical, Inc. and EnteroMedics, Inc. Prior to that, he created the marketing and sales department and played critical product development roles at Intuitive Surgical, Inc.

Mr. Hawkins has a Masters in Business Administration from the Stanford Graduate School of Business and a Bachelors of Science in Economics from The Wharton School at the University of Pennsylvania.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company�s flagship product is the Powerlink System�, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix�s Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements relating to the continued growth of Endologix�s business, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward-looking statements. Please refer to the Company�s Annual Report on Form 10-K for the year ended December 31, 2007, and the Company�s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024